Influence of gemfibrozil on high-density lipoproteins |
| |
Authors: | Charles Glueck |
| |
Affiliation: | From the Lipid Research, General Clinical Research Center Division, University of Cincinnati College of Medicine, Cincinnati, Ohio U.S.A. |
| |
Abstract: | In animal studies, gemfibrozil markedly elevates high-density lipoprotein (HDL) cholesterol levels, In humans with primary hyperlipoproteinemia and lipoprotein phenotypes IIA, IIB and IV, gemfibrozil, 1,200 mg/day, was associated with a 25%, 20% and 17% increase in HDL cholesterol, respectively. Gemfibrozil also substantially increased the ratio of HDL to total cholesterol, reflecting both an increase in HDL cholesterol and a decrease in very low density lipoprotein cholesterol and low-density lipoprotein cholesterol. Compared with a placebo in subjects with types IIA, IIB and IV lipoprotein phenotypes, therapy with gemfibrozil led to an increase of 33%, 34% and 23%, respectively, in the ratio of HDL cholesterol to total cholesterol. With gemfibrozil therapy, about 80% of subjects with hypertriglyceridemia had a reduction in triglycerides of 35 % or a return to normal levels; 50 % of subjects with hypercholesterolemia had a cholesterol reduction of 20% or a return to normal levels. |
| |
Keywords: | Address for reprints: Charles Glueck MD University of Cincinnati Medical Center Department of Medicine Division of Lipid Research 234 Goodman Street Room C2.2 Cincinnati Ohio 45267. |
本文献已被 ScienceDirect 等数据库收录! |
|